In lung cancer, the USP35 deubiquitination modification inhibits the proteasome-mediated degradation pathway (41), whereas in prostate cancer, METTL3 stabilizes RRBP1 through m6A modification (49). Here, RRBP1 is linked to lung carcinoma.